Among the candidate RCC tumor markers, NNMT, LCP1, and NM23A showed the highest features insignificance of difference in patients, the highest specificity in RCC compared to healthy individuals and several other cancers, and the best performances in the combination assay [9,10]. This evidence concerns the gene LCP1 and renal cell carcinoma.